Malignant mesothelioma: Medical oncology: standards, new trends, trials—the French experience
- 31 August 2004
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 45, S129-S131
- https://doi.org/10.1016/j.lungcan.2004.04.023
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesotheliomaEuropean Journal Of Cancer, 2000
- Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced CancerJournal of Clinical Oncology, 2000
- Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleuraCancer, 1999
- Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesotheliomaCancer, 1998
- Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesotheliomaEuropean Journal Of Cancer, 1997
- 62 Phase II study of paclitaxel (Taxol®) and cisplatin (CDDP) in advanced pleural malignant mesothelioma (MM)Lung Cancer, 1997
- Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesotheliomaCancer, 1994
- Intrapleural Recombinant IL-2 in Passive Immunotherapy for Malignant Pleural EffusionChest, 1993